

## Contents

**Preface** XIII

**List of Contributors** XV

**Color Plates** XIX

### Section A Molecular Aspects, Introduction and Purification 1

<b>1</b>	<b>Type I Interferons: Genetics and Structure</b>	<b>3</b>
	<i>Shamith A. Samarajiva, William Wilson and Paul J. Hertzog</i>	
1.1	Introduction	3
1.2	The Type I IFN Genetic Locus	4
1.3	Type I IFN Genes	7
1.3.1	IFN- $\alpha$	7
1.3.2	IFN- $\beta$	7
1.3.3	IFN- $\omega$	8
1.3.4	IFN- $\kappa$	8
1.3.5	IFN- $\varepsilon$	9
1.3.6	IFN- $\zeta$ (Limitin)	9
1.3.7	IFN- $\tau$	9
1.3.8	IFN- $\delta$	10
1.3.9	IFN- $\nu$	10
1.4	Type I IFN Gene-regulatory Regions	11
1.5	Evolution of the Type I IFNs	15
1.5.1	Vertebrate IFN Genes	15
1.5.2	The Expansion and Divergence of the IFN Genes	20
1.6	Natural and Induced Mutations in IFN Genes	21
1.7	Secondary Structural Features of Type I IFNs	22
1.7.1	Conserved Amino Acid Residues	22
1.7.2	Post-translational Modifications of Type I IFNs	23
1.7.3	Conserved Cysteine Residues and Disulfide Bond Formation	24
1.8	The Structure of Type I IFNs	24
	References	27

<b>2</b>	<b>Activation of Interferon Gene Expression Through Toll-like Receptor-dependent and -independent Pathways</b>	<b>35</b>
	<i>Peyman Nakhaei, Suzanne Paz and John Hiscott</i>	
2.1	Introduction	35
2.2	IFN- $\beta$ Gene Transcription	39
2.3	IRF Family Members	40
2.4	Role of IRFs in Virus-mediated IFN Activation	41
2.4.1	IRF-3	41
2.4.2	IRF-5	47
2.4.3	IRF-7	48
2.5	IFN Signaling Pathways	49
2.5.1	TLR-dependent Signaling to IFN Activation	49
2.5.1.1	TLR Overview	49
2.5.1.2	TLR-3 Signaling	51
2.5.1.3	TLR-4 Signaling	53
2.5.1.4	TLR-7 Signaling	57
2.5.1.5	TLR-9 Signaling	57
2.5.2	TLR-independent Signaling	58
2.5.2.1	Retinoic-inducible Gene (RIG)-I Signaling	58
2.5.2.2	Melanoma Differentiation-associated Gene-5 ( <i>mda-5</i> )	59
2.6	Conclusions	61
	References	61
<b>3</b>	<b>Interferon Proteins: Structure, Production and Purification</b>	<b>73</b>
	<i>Dimitris Platis and Graham R. Foster</i>	
3.1	Introduction	73
3.2	The Structure of Type I IFNs	73
3.3	Production and Purification of Type I IFNs	75
3.3.1	Leukocyte-derived IFN – First Steps in Producing Commercial IFN	75
3.3.2	Lymphoblastoid IFN – Towards more Reliable Supplies of IFN	76
3.3.3	Cloned Type I IFNs – An Inexhaustible Supply of Therapeutic Material	76
3.4	Long-acting IFNs	78
3.5	Summary	79
	References	80
<b>4</b>	<b>Interferon-<math>\gamma</math>: Gene and Protein Structure, Transcription Regulation, and Actions</b>	<b>85</b>
	<i>Ana M. Gamero, Deborah L. Hodge, David M. Reynolds, Maria Cecilia Rodriguez-Galan, Mansour Mohamadzadeh and Howard A. Young</i>	
4.1	Introduction	85
4.2	IFN- $\gamma$ Gene Structure and Regulation	86
4.2.1	Transcriptional Regulation	86
4.2.2	Epigenetic Regulation	88
4.2.3	Post-transcriptional Regulation	90

4.3	IFN- $\gamma$ Signal Transduction	90
4.3.1	The JAK–STAT Signaling Pathway	91
4.3.2	Activation of Alternate Signaling Pathways	92
4.3.3	Regulation of IFN- $\gamma$ Signaling	93
4.4	IFN- $\gamma$ in T <sub>h</sub> Cell Development	95
4.4.1	Signaling Pathways Involved in T Cell Development	95
4.5	IFN- $\gamma$ and DCs	97
4.5.1	IFN- $\gamma$ and T Cell–DC Crosstalk	97
4.5.2	Signals through Toll-like Receptors (TLRs) Activate DCs and Influence IFN- $\gamma$ Expression	99
4.6	IFN- $\gamma$ – Role in Tumor Development and Growth	100
4.6.1	IFN- $\gamma$ in Tumor Growth and Survival	100
4.6.2	Inhibition of Angiogenesis by IFN- $\gamma$	101
4.6.3	Role of IFN- $\gamma$ in Promoting Immune Responses against Tumors	102
4.7	Summary	103
	References	104
<b>5</b>	<b>Interferon and Related Receptors</b>	<b>113</b>
	<i>Sidney Pestka and Christopher D. Krause</i>	
5.1	Introduction	113
5.2	IFNs and IFN-like Molecules in Brief	113
5.3	The Receptors	114
5.3.1	Receptor Nomenclature	115
5.4	The Type I IFN Receptor	116
5.4.1	Discovery of the Type I Receptor Complex	117
5.4.2	Diversity of the Interaction of Type I IFNs with the Receptor	119
5.5	The Type II IFN (IFN- $\gamma$ ) Receptor	121
5.5.1	Chromosomal Localization of the IFN- $\gamma$ Receptor Ligand-binding Chain and Discovery of Two Chains Required for Activity	121
5.5.2	The IFN- $\gamma$ R1 Chain	123
5.5.3	The Second Receptor Chain (IFN- $\gamma$ R2)	123
5.5.4	The Functional IFN- $\gamma$ R Complex	124
5.5.4.1	Specificity of Ligand Binding	124
5.5.4.2	Specificity of the Interactions of the Two Chains	124
5.5.5	Specificity of Signal Transduction	124
5.5.6	Receptor Structure	125
5.5.7	Preassembly of the Receptor Complex	126
5.6	The IL-28R1 and -10R2 Receptor Complex	127
5.7	Overview of Multichain Receptors	128
5.8	Global Summary	128
	References	129
<b>6</b>	<b>Type III Interferons: The Interferon-<math>\lambda</math> Family</b>	<b>141</b>
	<i>Sergei V. Kotenko and Raymond P. Donnelly</i>	
6.1	Introduction	141

VIII | Contents

6.2	The Class II Cytokine Receptor Family (CRF2) and their Ligands	142
6.3	Genomic Structure	145
6.4	Receptor Complex and Signaling	148
6.5	Biological Activities	152
6.6	The Murine IFN- $\lambda$ Antiviral System	154
6.7	Evolution of the IFN Family	156
6.8	Therapeutic Potential	157
6.9	Conclusions	158
	References	158

**Section B Biological Properties** 165

<b>7</b>	<b>Biological Actions of Type I Interferons</b>	167
	<i>Melissa M. Brierley, Jyothi Kumaran and Eleanor N. Fish</i>	
7.1	Introduction	167
7.2	Sources of Type I IFN Production and Secretion	167
7.3	Type I IFN Interactions with the Receptor Complex	168
7.3.1	Structure and Functional Regions of Type I IFNs	168
7.3.2	IFN Domains Mediating Interactions with IFNAR-2	168
7.3.3	IFNAR-2 Domains Mediating Interactions with IFNs	170
7.3.4	IFN- $\alpha$ Interaction with IFNAR-2	172
7.3.5	IFN- $\beta$ Interaction with IFNAR-2	173
7.3.6	Type I IFN Interactions with IFNAR-1	174
7.3.7	IFNAR-1 Receptor Interaction with Glycosphingolipids	174
7.3.8	Residues in Type I IFNs that Mediate Biological Responses	175
7.4	Type I IFN-induced Signaling Cascades	175
7.4.1	The JAK-STAT (Signal Transducers and Activators of Transcription) Pathway	175
7.4.1.1	The Importance of STAT-1 and -2 in Type I IFN Signaling	178
7.4.2	Other IFN-inducible Signaling Cascades	179
7.4.2.1	The CrkL Pathway	179
7.4.2.2	The IRS Pathway	179
7.4.2.3	The p38 Mitogen-activated Protein Kinases (MAPK) Pathway	181
7.4.2.4	The Vav Protooncogene and IFN Signaling	182
7.4.2.5	The Protein Kinase C (PKC) Family and IFN Signaling	182
7.5	IFN-inducible Biological Responses	183
7.5.1	IFN-inducible Antiviral Responses	183
7.5.1.1	PKR	186
7.5.1.2	2'-5'-OAS/RNase L	186
7.5.1.3	Mx	187
7.5.1.4	Other IFN-inducible Antiviral Effectors	188
7.5.2	IFN-inducible Growth-inhibitory Responses	188
7.5.3	IFN-inducible Immunomodulation	190
7.6	Summary	192
	References	193

<b>8</b>	<b>Interferons and Apoptosis – Recent Developments</b>	<b>207</b>
	<i>Michael J. Clemens and Ian W. Jeffrey</i>	
8.1	Introduction	207
8.2	The Role of IFN-regulated Genes in the Control of Apoptosis	209
8.2.1	Proapoptotic Genes Induced by IFNs	209
8.2.2	p53 and IFN-induced Apoptosis	209
8.2.3	The Ribonuclease (RNase) L System	210
8.3	The Protein Kinase PKR and the Phosphorylation of Polypeptide Chain Initiation Factor eIF2 $\alpha$	212
8.3.1	Regulation of Apoptosis by PKR	212
8.3.2	The Role of eIF2 $\alpha$ Phosphorylation	212
8.4	IFNs and the Apoptotic Effects of TRAIL	215
8.4.1	TRAIL Induction	215
8.4.2	TRAIL Activity	215
8.5	Signal Transduction Pathways for IFN-mediated Effects on Apoptosis	218
8.6	The Antiapoptotic Effects of IFNs	219
8.7	Conclusions	220
	Acknowledgments	220
	References	221
<b>9</b>	<b>Viral Defense Mechanisms against Interferon</b>	<b>227</b>
	<i>Santanu Bose and Amiya K. Banerjee</i>	
9.1	Introduction	227
9.2	Innate Immune Antiviral Defense Mechanisms of Host Cells	227
9.3	Evasion of IFN-mediated Antiviral Response	231
9.3.1	Nonsegmented Negative-strand RNA Viruses	232
9.3.1.1	Paramyxoviruses	232
9.3.1.2	Filovirus	242
9.3.1.3	Rhabdovirus	242
9.3.2	Segmented Negative-strand RNA Viruses	242
9.3.2.1	Orthomyxovirus	243
9.3.2.2	Bunyaviruses	243
9.3.3	Positive-sense ssRNA Viruses	244
9.3.3.1	Picornaviruses	244
9.3.3.2	Flaviviruses	244
9.3.3.3	Coronavirus	246
9.3.4	dsRNA Viruses	247
9.3.5	RNA and DNA Reverse-transcribing Viruses	247
9.3.5.1	Retrovirus	247
9.3.5.2	Hepadnavirus	248
9.3.6	dsDNA Viruses	248
9.3.6.1	Adenovirus	248
9.3.6.2	Poxvirus	248
9.3.6.3	Herpesvirus	250

x | Contents

- 9.3.6.4 Papillomavirus 252
- 9.4 Concluding Remarks 253
- References 254

**Section C Clinical Applications 275**

**10 Overview of Clinical Applications of Type I Interferons 277**

*Frank Müller*

- 10.1 Introduction 277
- 10.2 Biological Effects 277
- 10.3 Type I IFN Products Currently Available or Under Development 278
- 10.4 Pharmacokinetics 284
  - 10.4.1 IFN- $\alpha$  284
  - 10.4.2 IFN- $\beta$  285
- 10.5 Clinical Applications of Type I Interferons 285
  - 10.5.1 Chronic hepatitis B (CHB) 286
  - 10.5.2 Chronic hepatitis C (CHC) 288
  - 10.5.3 Chronic hepatitis D (CHD) 290
  - 10.5.4 Hairy Cell Leukemia (HCL) 290
  - 10.5.5 Renal Cell Carcinoma (RCC) 291
  - 10.5.6 Basal Cell Carcinoma (BCC) 292
  - 10.5.7 Malignant Melanoma 292
  - 10.5.8 Kaposi Sarcoma (KS) 292
  - 10.5.9 Multiple Myeloma 293
  - 10.5.10 Chronic myelogenous leukemia (CML) 294
  - 10.5.11 Non-Hodgkinis lymphoma (NHL) 295
  - 10.5.12 Laryngeal Papillomatosis 295
  - 10.5.13 Mycosis Fungoides (MF) 296
  - 10.5.14 Condyloma Acuminata 296
  - 10.5.15 Multiple Sclerosis (MS) 297
- 10.6 IFN Toxicity 298
- 10.7 Type I IFNs in the Future 299
- References 300

**11 Clinical Applications of Interferon- $\gamma$  309**

*Christine W. Czarniecki and Gerald Sonnenfeld*

- 11.1 Introduction 309
- 11.2 IFN- $\gamma$  – The Molecule 311
- 11.3 FDA-approved Indications: Established Benefit and Risks 311
  - 11.3.1 Chronic Granulomatous Disease (CGD) 311
  - 11.3.2 Osteopetrosis 313
  - 11.3.3 Adverse Reactions 314
- 11.4 Infectious Diseases 314
  - 11.4.1 Mycobacterial Infection 314
    - 11.4.1.1 Leprosy 314

11.4.1.2	<i>Mycobacterium avium</i> Infection	315
11.4.1.3	Tuberculosis (TB)	315
11.4.2	Leishmaniasis	317
11.4.3	Opportunistic Infections in HIV Disease	317
11.5	Infection Following Serious Trauma	318
11.6	Atopic Dermatitis (AD)	321
11.7	Idiopathic Pulmonary Fibrosis (IPF)	322
11.8	Systemic Sclerosis (SSc)	326
11.9	Radiation-induced Fibrosis	326
11.10	Chronic Hepatitis	327
11.11	Oncology Indications: Ovarian Cancer	329
11.12	Conclusions	330
	References	331
<b>Section D</b>	<b>Measurement of Interferons and Anti-Interferons</b>	<b>337</b>
<b>12</b>	<b>Measurement of Interferon Activities</b>	<b>339</b>
	<i>Tony Meager</i>	
12.1	Introduction	339
12.2	The IFNs: Mechanisms of Action, Protein Induction and Biological Activities	340
12.2.1	Mechanisms of Action	340
12.2.2	Protein Induction	342
12.2.3	Biological Activities	344
12.2.3.1	Antiviral Activity	344
12.2.3.2	Antiproliferative Activity	344
12.2.3.3	Immunomodulatory Activity	345
12.3	Measurement of Biological Activities of IFNs	345
12.3.1	General Considerations	345
12.3.2	Biological Standards for IFNs	346
12.3.3	Practical Considerations for IFN Preparations	348
12.3.4	Antiviral Assays	349
12.3.5	Antiproliferative Assays	351
12.3.6	IFN-inducible Protein Assays	354
12.3.6.1	Bioimmunoassays	354
12.3.6.2	Enzyme Expression and Reporter Gene Assays	356
12.3.7	Assays Based on Intracellular Signaling Intermediates	361
12.3.8	Assay Design and Data Analysis	363
12.4	Regulatory Landscape	365
	Acknowledgments	366
	References	366

<b>13</b>	<b>The Development and Measurement of Antibodies to Interferon</b>	<b>375</b>
	<i>Sidney E. Grossberg and Yoshimi Kawade</i>	
13.1	Introductory Perspective	375
13.1.1	Immunological Perspective	375
13.1.2	Antibodies to Self-antigens	376
13.2	NAbs	377
13.2.1	Neutralization Bioassay Design	378
13.2.1.1	The Constant IFN Method	379
13.2.1.2	The Constant Antibody Method	380
13.2.2	Theoretical Analyses	382
13.2.3	Experimental Analyses	383
13.2.4	Standardization and the Reporting of Neutralization Results	383
13.2.5	A Solution to the Problem of NAb Unitage	385
13.3	Immunoassays for Non-NAbs	387
13.4	Epitope Analysis	388
13.5	Development of Antibodies during IFN Therapy	390
13.5.1	Antibodies to IFN- $\alpha$	391
13.5.2	Antibodies to IFN- $\beta$	392
13.6	Summary	394
	References	395
	<b>Index</b>	<b>401</b>